Xencor (XNCR) Price & Analysis

Compare

251 Followers

XNCR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.07 - $27.24

Previous CloseN/A

Volume126.93K

Average Volume (3M)644.10K

Market Cap

$515.67M

Enterprise Value$352.92M

Total Cash (Recent Filing)$469.57M

Total Debt (Recent Filing)$67.82M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Nov 10, 2025

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding71,323,044

10 Day Avg. Volume693,576

30 Day Avg. Volume644,104

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)2.21

Price to Sales (P/S)13.53

P/FCF Ratio-7.18

Enterprise Value/Market Cap0.68

Enterprise Value/Revenue2.71

Enterprise Value/Gross Profit2.77

Enterprise Value/Ebitda-2.23

Forecast

1Y Price Target

$24.39

Price Target Upside248.43% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical TrialsXencor recently initiated the Phase IIb XENITH-UC study with the TL1A antibody XmAb942 in ulcerative colitis following positive initial Phase I results.

Financial PerformanceXNCR ended with $663.8M in cash and equivalents, with cash runway guidance extending into 2028.

Pipeline DevelopmentXencor's platforms have shown proof-of-concept of efficacy and safety across multiple assets and indications.

Bears Say

Market CompetitionIts potency and convenience is unmatched by current Phase II/III competitors, lending confidence in the recently initiated Phase IIb UC trial.

Regulatory ProgressInitial Phase I data with XmAb819 in renal cell carcinoma will be presented at a medical conference in the fourth quarter of 2025.

Xencor News

Xencor price target lowered to $26 from $31 at Wedbush

Wedbush analyst David Nierengarten lowered the firm’s price target on Xencor (XNCR) to $26 from $31 and keeps...

6d ago

XNCR

Xencor reports Q2 EPS (41c) , consensus (71c)

Reports Q2 revenue $43.6M, consensus $22.6M. “Xencor (XNCR) is focused on execution of our clinical studies, evaluating four...

7d ago

XNCR

Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. Study Overview: Xencor Inc. recently completed a...

6d ago

XNCR

Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. Study Overview: Xencor Inc. is conducting a...

6d ago

XNCR

Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

6d ago

XNCR

Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

6d ago

XNCR

Xencor, Inc. Reports Revenue Growth Amidst Continued Losses

Xencor Inc. ( ($XNCR) ) has released its Q2 earnings. Here is a breakdown of the information Xencor...

6d ago

XNCR

Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. In a recent update, Xencor Inc. has...

8d ago

XNCR

Xencor Appoints Raymond Deshaies to Board of Directors

An announcement from Xencor ( ($XNCR) ) is now available. On July 31, 2025, Xencor announced the appointment...

13d ago

XNCR

Xencor’s XmAb819 Study: A Promising Step in Renal Cell Carcinoma Treatment

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. Study Overview: Xencor Inc. is conducting a...

13d ago

XNCR

Xencor’s Phase 2 Study on Vudalimab in Prostate Cancer: Key Update and Market Impact

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. In a recent update, Xencor Inc. announced...

27d ago

XNCR

Xencor’s Promising Developments in Autoimmune and Oncology Drive Buy Rating

William Blair analyst Matt Phipps has reiterated their bullish stance on XNCR stock, giving a Buy rating today....

2M ago

XNCR

Xencor price target lowered to $6 from $22 at Barclays

Barclays lowered the firm’s price target on Xencor (XNCR) to $6 from $22 and keeps an Underweight rating...

3M ago

XNCR

Xencor reports Q1 EPS (66c), consensus (58c)

Reports Q1 revenue $32.7M, consensus $24.8M. “Recently presented interim Phase 1 results support XmAb942 as a high potency...

3M ago

XNCR

XNCR FAQ

What was Xencor Inc’s price range in the past 12 months?

Xencor Inc lowest stock price was $7.07 and its highest was $27.24 in the past 12 months.

What is Xencor Inc’s market cap?

Xencor Inc’s market cap is $515.67M.

When is Xencor Inc’s upcoming earnings report date?

Xencor Inc’s upcoming earnings report date is Nov 10, 2025 which is in 89 days.

How were Xencor Inc’s earnings last quarter?

Xencor Inc released its earnings results on Aug 06, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.72 by $0.31.

Is Xencor Inc overvalued?

According to Wall Street analysts Xencor Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xencor Inc pay dividends?

Xencor Inc does not currently pay dividends.

What is Xencor Inc’s EPS estimate?

Xencor Inc’s EPS estimate is -0.69.

How many shares outstanding does Xencor Inc have?

Xencor Inc has 71,323,044 shares outstanding.

What happened to Xencor Inc’s price movement after its last earnings report?

Xencor Inc reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.72. Following the earnings report the stock price went down -2.27%.

Which hedge fund is a major shareholder of Xencor Inc?

Currently, no hedge funds are holding shares in XNCR

Xencor Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.22%

Trailing 12-Months

Asset Growth

4.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xencor Inc

Xencor, Inc. is a biopharmaceutical company focused on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology platform to create novel therapeutics that enhance the efficacy and safety of antibody-based treatments. Xencor's pipeline includes multiple drug candidates that are in various stages of clinical development, targeting significant unmet medical needs in oncology and other therapeutic areas.

Xencor (XNCR) Earnings & Revenues

Historic Earnings Reports

XNCR Stock 12 Month Forecast

Average Price Target

$24.39

▲(248.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","39":"$39","13.5":"$13.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.5,22,30.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.98,10.28923076923077,12.598461538461539,14.907692307692308,17.216923076923077,19.526153846153846,21.835384615384616,24.144615384615385,26.453846153846154,28.763076923076923,31.072307692307692,33.38153846153846,35.690769230769234,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.98,9.242307692307692,10.504615384615384,11.766923076923078,13.02923076923077,14.291538461538462,15.553846153846155,16.816153846153846,18.07846153846154,19.340769230769233,20.603076923076923,21.865384615384617,23.127692307692307,{"y":24.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.98,7.827692307692308,7.6753846153846155,7.523076923076923,7.370769230769231,7.218461538461539,7.0661538461538465,6.913846153846154,6.7615384615384615,6.60923076923077,6.456923076923077,6.304615384615385,6.1523076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.49,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >